Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Whittaker

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
The Journal of Investigative Dermatology|June 22, 2012
NOTCH1 signaling as a therapeutic target in Sézary syndromeLeslie van der Fits, Yongjun Qin, Jacoba J Out-Luiting, et al.
Journal of Cutaneous Pathology|November 27, 2013
Evaluation of follicular T-helper cells in primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma and dermatitisMina S Ally, Ranganna Y Prasad Hunasehally, Manuel Rodriguez-Justo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2006
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndromeFranz Trautinger, Robert Knobler, Rein Willemze, et al.
Leukemia & Lymphoma|August 31, 2017
Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapyMadeleine Duvic, Susan E Bates, Richard Piekarz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012Reinhard Dummer, Pietro Quaglino, Jürgen C Becker, et al.
Leukemia & Lymphoma|March 21, 2015
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaEllen J Kim, Youn H Kim, Alain H Rook, et al.
The Journal of Investigative Dermatology|December 17, 2016
Increased Expression of PLS3 Correlates with Better Outcome in Sézary SyndromeStéphanie E Boonk, Willem H Zoutman, Hein Putter, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2021
Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trialAmy C M Musiek, Sean Whittaker, Steven M Horowitz, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Leukemia & Lymphoma|July 31, 2012
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsinYoun H Kim, Marie-France Demierre, Ellen J Kim, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Investigative Dermatology|June 22, 2012
NOTCH1 signaling as a therapeutic target in Sézary syndromeLeslie van der Fits, Yongjun Qin, Jacoba J Out-Luiting, et al.
Journal of Cutaneous Pathology|November 27, 2013
Evaluation of follicular T-helper cells in primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma and dermatitisMina S Ally, Ranganna Y Prasad Hunasehally, Manuel Rodriguez-Justo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2006
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndromeFranz Trautinger, Robert Knobler, Rein Willemze, et al.
Leukemia & Lymphoma|August 31, 2017
Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapyMadeleine Duvic, Susan E Bates, Richard Piekarz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012Reinhard Dummer, Pietro Quaglino, Jürgen C Becker, et al.
Leukemia & Lymphoma|March 21, 2015
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaEllen J Kim, Youn H Kim, Alain H Rook, et al.
The Journal of Investigative Dermatology|December 17, 2016
Increased Expression of PLS3 Correlates with Better Outcome in Sézary SyndromeStéphanie E Boonk, Willem H Zoutman, Hein Putter, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2021
Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trialAmy C M Musiek, Sean Whittaker, Steven M Horowitz, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Leukemia & Lymphoma|July 31, 2012
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsinYoun H Kim, Marie-France Demierre, Ellen J Kim, et al.
Pageof 9